{
    "Question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and low disease activity receive csDMARD monotherapy or csDMARD combination (double or triple) therapy?",
    "Comparison": {
        "csDMARD double combination therapy versus csDMARD monotherapy. Data based on indirect RCT evidence.": {
            "filename": "PICO 3a_Comparison 1.json",
            "Explanations": {
                "a": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment in both studies, high risk of attrition bias in one of the two studies.",
                "b": "Downgraded by one level due to serious indirectness. The evidence is based on a population with moderate to high disease activity.",
                "c": "csDMARD double therapy includes: MTZ+SSZ",
                "d": "csDMARD monotherapy includes: MTX or SSZ",
                "e": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment.",
                "f": "Downgraded by one level due to serious imprecision. Low sample size.",
                "g": "Downgraded by two levels due to very serious imprecision. Confidence intervals includes both values suggesting benefit and values suggesting harm. Small sample size, very low number of events."
            }
        },
        "csDMARD triple combination therapy vs csDMARD monotherapy. Data based on direct RCT evidence.": {
            "filename": "PICO 3a_Comparison 2.json",
            "Explanations": {
                "a": "Downgraded by one level due to serous imprecision. Small sample size.",
                "b": "csDMARD triple therapy includes: MTX+SSZ+HCQ",
                "c": "csDMARD monotherapy includes: MTX",
                "d": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Small sample size.",
                "e": "Downgraded by one level due to serious imprecision. Small sample size."
            }
        }
    },
    "References": {
        "1": "Dougados M. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Annals of the Rheumatic Diseases. 1999;58(4):220.",
        "2": "Haagsma C, van Riel P, de Jong A, van de Putte L. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. British Journal of Rheumatology. 1997;36(10):1082.",
        "3": "de Jong PHP, Hazes JM, Barendregt PJ, Huisman M, van Zeben D, van der Lubbe PA, et al. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Annals of the Rheumatic Diseases. 2013;72(1):72.",
        "4": "de Jong PHP, Hazes JM, Buisman LR, Barendregt PJ, van Zeben D, van der Lubbe PA, et al. Best cost-effectiveness and worker productivity with initial triple DMARD therapy compared with methotrexate monotherapy in early rheumatoid arthritis: cost-utility analysis of the tREACH trial. Rheumatology. 2016;55(12):2138."
    }
}